SAN ANTONIO, Texas, United States, April 7, 2026
bioAffinity Technologies, Inc. announced that its CyPath® Lung diagnostic test will be featured at the prestigious Cleveland Clinic “Advances in Early Lung Cancer Detection” symposium on April 16, 2026. The invitation-only event will bring together global experts to discuss innovations in lung cancer screening, early detection technologies, and clinical decision-making, highlighting CyPath® Lung as a noninvasive diagnostic solution with strong clinical potential.
Noninvasive Diagnostic Innovation Targets Early Lung Cancer Detection
CyPath® Lung is a noninvasive, sputum-based diagnostic test designed to aid in the early detection of lung cancer in high-risk patients, particularly those presenting with indeterminate pulmonary nodules. The test combines advanced flow cytometry with proprietary artificial intelligence (AI) to analyze the lung microenvironment and identify cancer and cancer-associated cells, providing clinicians with actionable diagnostic insights.
Clinical data have demonstrated that CyPath® Lung delivers high diagnostic performance, with 92% sensitivity, 87% specificity, and 88% overall accuracy, enabling detection of cancer at early stages such as Stage 1A, when treatment outcomes are significantly improved. These capabilities position the test as a valuable adjunct to existing diagnostic pathways, helping clinicians make more informed and timely decisions.
Importantly, the test offers a noninvasive alternative to traditional diagnostic procedures, reducing reliance on biopsies and other invasive interventions, which can carry risks and increase healthcare costs.
Advertisement
Addressing Growing Clinical Challenges in Lung Cancer Diagnosis
The increasing use of lung cancer screening and imaging technologies has led to a rise in the detection of indeterminate pulmonary nodules, creating a growing challenge for clinicians in distinguishing between benign and malignant lesions. CyPath® Lung addresses this gap by providing additional diagnostic clarity, supporting clinical decision-making and helping to reduce unnecessary invasive procedures.
The test is particularly valuable in managing high-risk patient populations, including individuals with a history of smoking or prior cancer, where early detection is critical for improving survival rates. Additionally, CyPath® Lung can be used to monitor lung cancer survivors for recurrence, expanding its utility across the continuum of care.
At the Cleveland Clinic symposium, bioAffinity’s Chief Medical Officer will participate in a panel discussion focused on lung nodule management, emphasizing the importance of integrating innovative diagnostic tools into clinical workflows.
Advancing AI-Driven Diagnostics and Clinical Adoption
CyPath® Lung represents a broader trend toward AI-driven precision diagnostics, where advanced technologies are leveraged to improve accuracy, efficiency, and patient outcomes. By incorporating machine learning algorithms and biomarker analysis, the test enhances the ability to detect cancer at earlier stages and supports personalized patient management strategies.
The test is currently marketed as a Laboratory Developed Test (LDT) under Clinical Laboratory Improvement Amendments (CLIA) regulations, highlighting its compliance with quality and laboratory standards required for clinical use. As regulatory frameworks for diagnostics continue to evolve, technologies like CyPath® Lung are expected to play a key role in shaping the future of early cancer detection.
The continued recognition of CyPath® Lung at major scientific forums underscores its growing importance in the field of oncology diagnostics and translational medicine, as well as its potential to improve clinical outcomes through earlier and more accurate detection.
The inclusion of CyPath® Lung at the Cleveland Clinic symposium highlights the growing importance of noninvasive, AI-driven diagnostic technologies in lung cancer detection. With strong clinical performance, broad applicability, and the ability to reduce invasive procedures, CyPath® Lung represents a significant advancement in early cancer detection and precision diagnostics.
As healthcare systems increasingly prioritize early diagnosis and cost-effective care, innovations like CyPath® Lung are poised to play a critical role in improving patient outcomes and transforming the diagnostic landscape.
Source: bioAffinity Technologies press release
